Previous 10 |
HSGX -43% on pricing public offering of common stock and warrants. More news on: Histogenics Corporation, KemPharm, Aytu BioScience, Inc., Stocks on the move, Top stock market news, , Read more ...
Thinly traded Xencor (NASDAQ: XNCR ) slips 7% premarket following its announcement of topline results from a Phase 2 clinical trial evaluating XmAb 5871 in patients with systemic lupus erythematosus (SLE). The data will be presented at the American College of Rheumatology (ACR) An...
MONROVIA, Calif. , Oct. 5, 2018 /PRNewswire/ -- Xencor, Inc. (NASDAQ:XNCR), a clinical-stage biopharmaceutical company developing monoclonal antibodies for the treatment of autoimmune disease, asthma and allergic diseases, and cancer, today announced topline results from the randomiz...
MONROVIA, Calif. , Sept. 25, 2018 /PRNewswire/ -- Xencor, Inc. (NASDAQ: XNCR), a clinical-stage biopharmaceutical company developing engineered monoclonal antibodies for the treatment of autoimmune diseases, asthma and allergic diseases and cancer, today announced that company m...
News, Short Squeeze, Breakout and More Instantly...
2024-07-05 16:36:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...
Xencor, Inc. (NASDAQ:XNCR), a clinical-stage biopharmaceutical company developing engineered antibodies for the treatment of cancer and other serious diseases, announced it will regain exclusive worldwide rights to plamotamab, a CD20 x CD3 bispecific T-cell engager, which Xencor advanced through ...
2024-06-04 04:00:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...